Table 3

Therapeutic outcomes of adalimumab therapy, expressed per-eye ‘at risk’

Outcome6 weeks6 months12 months18 months24 months30 months
Per-eyeCharacteristic required to be ‘at risk’Events/at riskRate per 100 (95% CI)Events/at riskRate per 100 (95% CI)Events/at riskRate per 100 (95% CI)Events/at riskRate per 100 (95% CI)Events/at riskRate per 100 (95% CI)Events/at riskRate per 100 (95% CI)
Active eyes
 Improvement of anterior
 chamber cells by 2 grades
≥1+  cells at baseline11/11100
(70.0 to 100*)
9/1090.0
(57.4 to 100*)
7/887.5
(50.7 to 99.9)
5/5100
(51.1 to 100*)
4/4100
(45.4 to 100*)
3/3100
(38.3 to 100*)
 Improvement of vitreous haze by 2 grades≥1+  haze at baseline5/1050.0
(23.7 to 76.3)
6/1060.0
(31.1 to 83.3)
7/887.5
(50.7 to 99.9)
4/757.1
(25.0 to 84.2)
5/683.3
(41.8 to 99.0)
6/6100
(55.7 to 100*)
 Improvement of macular oedemaMacular oedema at baseline1/1100
(16.8 to 100*)
1/1100
(16.8 to 100*)
1/1100
(16.8 to 100*)
1/1100
(16.8 to 100*)
0/0na0/0na
 Improvement of logMAR to ≤0.3logMAR >0.3 at baseline5/1145.5
(21.3 to 72.0)
2/1020.0
(4.6 to 52.1)
3/742.9
(15.8 to 75.0)
2/540.0
(11.6 to 77.1)
2/450.0
(15.0 to 85.0)
3/3100
(38.3 to 100*)
Inactive eyes
 Maintenance of anterior chamber cells ≤0.5+≤0.5+  cells at baseline16/1888.9
(66.0 to 98.1)
18/18100
(79.3 to 100*)
15/15100
(76.1 to 100*)
4/4100
(45.4 to 100*)
2/2100
(29.0 to 100*)
1/250.0
(9.5 to 90.5)
 Maintenance of vitreous haze ≤0.5+≤0.5+  haze at baseline15/1693.8
(69.7 to 100*)
17/1894.4
(72.4 to 100*)
15/15100
(76.1 to 100*)
4/4100
(45.4 to 100*)
2/2100
(29.0 to 100*)
2/2100
(29.0 to 100*)
 Improvement of macular oedemaMacular oedema at baseline0/10
(0† to 83.3)
0/20
(0† to 71.0)
0/20
(0† to 71.0)
0/0na0/0na0/0na
 Improvement of logMAR to ≤0.3logMAR >0.3 at baseline1/333.3
(5.6 to 79.8)
1/333.3
(5.6 to 79.8)
1/250.0
(9.5 to 90.5)
0/0na0/0na0/0na
  • Macular oedema was defined as a CMT of ≥340 µm for eyes measured with an OCT Spectralis and ≥320 µm for eyes measured with a Cirrus OCT. Improvement of macular oedema refers to a reduction in the CMT to <340 for those measured with an OCT Spectralis and <320 for those measured with a Cirrus OCT.

  • *Indicates the Agresti-Coull CI was clipped at the upper endpoint.

  • †Indicates the Agresti-Coull CI was clipped at the lower endpoint.

  • CMT, central macular thickness; OCT, optical coherence tomography; logMAR, logarithm of the minimum angle of resolution.